CLINICAL TRIAL SUMMARY

MDACC Study No:2008-0384 (clinicaltrials.gov NCT No: NCT00761644)
Title:A Phase I Trial of Doxil, Bevacizumab and Temsirolimus
Principal Investigator:Daniel Karp
Treatment Agent:Bevacizumab; Doxil; Everolimus; Temsirolimus
Study Status:Open
Study Description:The goal of this clinical research study is to learn the highest safe doses of
the combination of Doxil (liposomal doxorubicin), Avastin (bevacizumab), and
Torisel (Temsirolimus) that can be given to patients with advanced cancer that
has spread or is unable to be surgically removed. The safety and effectiveness
of this combination of drugs will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Advanced Cancers
Phase of Study:Phase I
Treatment Agents:Bevacizumab
Doxil
Everolimus
Temsirolimus
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:not applicable
Supported By:N/A
Return Visit:Days 1, 8 and 15 of every 3 week cycle
Home Care:As available above


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Daniel Karp
Dept:Investigational Cancer Therapeutics
For Clinical Trial Enrollment:713-563-1930
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults